Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17702295 | 0.95 | MAPK1 (0.31) | MAPK1KDM4EATMALDH1A1HPGD | |
| SCHEMBL17702318 | 0.95 | MAPK1 (0.31) | MAPK1KDM4EATMALDH1A1HPGD | |
| SCHEMBL17702319 | 0.94 | MAPK1 (0.32) | MAPK1KDM4EATMALDH1A1HPGD | |
| SCHEMBL17702305 | 0.93 | MAPK1 (0.31) | MAPK1KDM4EATMALDH1A1HPGD | |
| SCHEMBL17702300 | 0.93 | MAPK1 (0.31) | MAPK1KDM4EATMALDH1A1HPGD | |
| SCHEMBL17702299 | 0.93 | MAPK1 (0.31) | MAPK1KDM4EATMALDH1A1HPGD | |
| SCHEMBL17702302 | 0.92 | MAPK1 (0.30) | MAPK1KDM4EATMALDH1A1HPGD | |
| SCHEMBL17702306 | 0.92 | MAPK1 (0.30) | MAPK1KDM4EATMALDH1A1HPGD | |
| SCHEMBL17702322 | 0.92 | MAPK1 (0.30) | MAPK1KDM4EATMALDH1A1HPGD | |
| SCHEMBL17702123 | 0.91 | MAPK1 (0.36) | MAPK1KDM4EATMALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9741939-B2 | Condensed cyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-08-22 | — | — | US | disclosed |
| US-9741939-B2 | Condensed cyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-08-22 | — | — | US | disclosed |
| US-20160118593-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-04-28 | — | — | US | disclosed |
| US-20160118593-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160118593-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CCNA1, CCNT1 | MAPK1 412/4885KDM4E 3185/4885ATM 2990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.